B
1.66
0.01 (0.61%)
| Previous Close | 1.65 |
| Open | 1.65 |
| Volume | 1,289,449 |
| Avg. Volume (3M) | 2,411,515 |
| Market Cap | 94,656,848 |
| Price / Book | 3.29 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 |
| Diluted EPS (TTM) | -3.54 |
| Total Debt/Equity (MRQ) | 27.58% |
| Current Ratio (MRQ) | 2.26 |
| Operating Cash Flow (TTM) | -113.53 M |
| Levered Free Cash Flow (TTM) | -74.11 M |
| Return on Assets (TTM) | -74.21% |
| Return on Equity (TTM) | -156.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Biomea Fusion, Inc. | Bearish | Bearish |
AIStockmoo Score
0.9
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.88 |
|
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 9.76% |
| % Held by Institutions | 45.04% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 18.00 (HC Wainwright & Co., 984.34%) | Buy |
| Median | 16.00 (863.86%) | |
| Low | 7.00 (Piper Sandler, 321.69%) | Buy |
| Average | 13.67 (723.49%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 2.01 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 24 Jun 2025 | 16.00 (863.86%) | Buy | 1.88 |
| 18 Jun 2025 | 16.00 (863.86%) | Buy | 1.91 | |
| Piper Sandler | 03 Jun 2025 | 7.00 (321.69%) | Buy | 2.49 |
| HC Wainwright & Co. | 06 May 2025 | 18.00 (984.34%) | Buy | 1.67 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |